4D Molecular Therapeutics (FDMT) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

4D Molecular Therapeutics (FDMT) overview

4D Molecular Therapeutics (FDMT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 85.2m and operating profit of USD -160m; the year-end share price was 7.50 USD and market capitalisation was USD 432m. 4D Molecular Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get 4D Molecular Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 506mFY 2025
Share price7.50 USDFY 2025 year end
RevenueUSD 85.2mFY 2025
Operating profitUSD -160mFY 2025
Net earningsUSD -140mFY 2025
Market capitalisationUSD 432mFY 2025 year end

About 4D Molecular Therapeutics

4D Molecular Therapeutics develops genetic medicines using its proprietary adeno-associated virus vector discovery and engineering platform. Its lead candidate, 4D-150, is in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, an inhaled gene therapy candidate for cystic fibrosis, and 4D-175, an investigational program for geographic atrophy.

Generate the 4D Molecular Therapeutics report

4D Molecular Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for 4D Molecular Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on 4D Molecular Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.